Background: In 2002, a previously healthy 69-year-old man travelled to France from the United States and presented to our hospital with a febrile illness that subsequently was determined to be babesiosis. The blood isolated from this patient served as a source for propagation of the Babesia microti R1 strain with subsequent sequencing and annotation of the parasite genome. Methods: Upon admission, we obtained a medical history, performed a physical examination, and examined his blood for the presence of a blood borne pathogen by microscopy, PCR and indirect immunofluorescence antibody testing. Once the diagnosis of babesiosis was made, we reviewed the literature to assess the distribution of B. microti-associated babesiosis cases in immunocompetent patients from outside the USA. Results: The patient recalled a tick bite during the previous month on Cape Cod, Massachusetts. The diagnosis was confirmed by identification of Babesia-infected red blood cells on blood smears, amplification of B. microti DNA in blood by PCR and the presence of B. microti antibody in the serum. This strain was the first isolate of B. microti to be fully sequenced and its annotated genome serves as a reference for molecular and cell biology studies aimed at understanding B. microti pathophysiology and developing diagnostic tests and therapies. A review of babesiosis cases demonstrates a worldwide distribution of B. microti and identifies potential emerging endemic areas where travelers may be at risk of contracting B. microti infection. Conclusion: This case provides clinical information about the patient infected with the R1 isolate and a review of travel risk, diagnosis and treatment of babesiosis in endemic and non-endemic areas.
Introduction
Babesia species are intra-erythrocytic protozoan parasites that cause babesiosis, a tick-borne infectious disease that occurs worldwide. 1 These parasites belong to the phylum Apicomplexa, which encompasses other protozoan parasites such as those that cause malaria, toxoplasmosis and cryptosporidiosis. Babesia microti, the causative agent of most human babesiosis cases, is transmitted to humans by hard bodied (Ixodes) tick vectors, the same ticks that transmit the agents of Lyme disease (Borrelia burgdorferi) and human granulocytic anaplasmosis (Anaplasma phagocytophilum).
2 Babesia microti also can be acquired through blood transfusion and is the most common transfusion-transmitted pathogen in the United States. 3 Transfusion-transmitted babesiosis (TTB) is a risk to the blood supply in endemic and non-endemic areas because infected blood from asymptomatic donors from endemic regions may be transported to non-endemic areas and donors that are asymptomatically infected in an endemic area may return to a nonendemic area and donate blood. 4, 5 Various screening strategies of blood supply have been implemented and have helped to reduce TTB incidence. [3] [4] [5] [6] Human babesiosis due to B. microti is endemic in the northeastern and northern midwestern United States and sporadically reported in Asia, Australia, Europe and South America. 2, [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] In 2011, the Institute of Medicine in the United States designated babesiosis an emerging health threat 19 and the United States Centers for Disease Control and Prevention (CDC) designated babesiosis as a nationally notifiable disease. 20 In 2012, the sequencing and annotation of the full B. microti genome was completed, an important advance in our understanding of B. microti biology and evolution. [21] [22] [23] The R1 strain that was sequenced is currently used as a reference genome to characterize the genetic diversity and pathogenicity of B. microti strains and to develop new diagnostic tests and therapies. 24 This manuscript describes the clinical case that led to the isolation of the B. microti R1 isolate and provides important information about babesiosis management in endemic and non-endemic areas.
Case Presentation
A 69-year-old previously healthy Caucasian male was in good health until he developed chills during a flight from the United States to France in the summer of 2002. Despite selfadministration of non-steroidal anti-inflammatory drugs (NSAIDs), he subsequently developed a frontal headache and purpuric rash, which continued until presentation to the Centre Hospitalier Bretagne Atlantique in Vannes, Brittany, France. He was a resident of New York City with a second residence in Cape Cod, Massachusetts. Over the course of 30 years the patient had traveled to Europe, South America, Asia and Australia. One month prior to hospitalization, he spent 2 weeks at his Cape Cod residence where he reported multiple tick bites. The patient was on no medications. His past medical history included appendectomy. On physical examination, the patient was awake, alert and oriented to person, place and time and in no acute distress. He was febrile to 105°F (rectal) with normal blood pressure and heart rate. There was no evidence of meningismus. Eye exam revealed no icterus. Skin examination revealed diffuse purpura of the lower extremities. ) and an elevated erythrocyte sedimentation rate (ESR) of 100 mm/h. Prothrombin time (PT) was slightly prolonged with an INR of 1.3. Serum electrolytes revealed a sodium of 134 mmol/l and potassium of 3.4 mmol/l. Serum creatinine was 1.37 mg/dl. Liver enzymes alanine aminotransferase (ALT), gammaglutamyl transpeptidase (GGT), alkaline phosphatase and total bilirubin were in normal range, and haptoglobin was undetectable. Aspartate transaminase (AST: 75 U/l) and lactate dehydrogenase (LDH: 700 U/l) levels were elevated. Marked elevations were noted in the acute phase protein fibrinogen (6600 mg/dl) and C-reactive protein (CRP: 286 mg/l).
Three blood cultures were performed and were negative. Lumbar puncture analysis revealed clear CSF with no cells and normal total protein and glucose. CSF culture revealed no growth of organisms. Urine analysis showed no evidence of leukocytes, nitrites or erythrocytes. Electrocardiography was normal. Abdominal echography showed a normal spleen and no other abnormalities except a hemangioma of the liver in segment VI. Tranthoracic echocardiography revealed normal ejection fraction, morphology and valvular function without evidence of pericardial effusion. Chest radiography demonstrated a mild interstitial infiltrate at the right lung base.
An initial peripheral blood smear suggested Plasmodium falciparum with a 3% parasitemia. Re-evaluation of the blood smear and morphology of parasites within the patient's red blood cells Babesia infection (Figure 1 ). Babesia microti DNA was amplified from blood using a Babesia PCR using the primer pair PIRO-A (5′AATACCCAATCCTGACACAGGG 3′) and antisense oligonucleotide primer PIRO-B (5′TTAAATACGAA TGCCCCCAAC 3′) amplifying a variable section of the 18S encoding gene. 25 Sequencing of the PCR product showed 95% homology to the 18S rDNA sequence of B. microti. Several Babesia serologic tests were performed using indirect immunofluorescence antibody tests (IFT) with polyvalent antihuman secondary antibody (Sigma, F6506) to discriminate between antibodies to different Babesia species. Markedly elevated antibody titer was detected for B. microti (1:16 400) with the presumption that reactivity to Babesia divergens (titer: 1:2048) and Babesia canis (titer: 1:512) were a result of cross-reactivity of B. microti antibody to antigens of these other Babesia species. The initial serological analysis for malaria showed negative IgM but positive IgG. The results of antibody testing for ehrlichiosis, syphilis (Treponema pallidum) and for HIV were negative. Lyme disease serology was performed to assess possible coinfection with B. burgdorferi. Borrelia burgdorferi IgG antibody was detected but no IgM. The patient had no previous history of Lyme disease. A diagnosis of acute Lyme disease was ruled out based on the absence of an erythema migrans rash and the absence of IgM antibody confirmed by western blot analysis.
The patient was diagnosed with severe babesiosis caused by B. microti and was given intravenous quinine (20 mg/kg body weight loading dose, followed by 10 mg/kg body weight every 8 h) for 4 days. The patient experienced a rapid defervescence following treatment with resolution of thrombocytopenia but experienced persistent hemolysis and mild renal insufficiency. After completion of 4 days of intravenous quinine, he was given oral quinine 500 mg thrice daily and clindamycin 300 mg thrice daily for another 10 days. By the end of the fifth hospital day, the patient recovered well with resolution of hemolysis and mild renal dysfunction. He was discharged with no residual symptoms.
Review and Discussion
The primary objective of this report is to describe the clinical presentation, diagnosis and therapy of human babesiosis case that led to the isolation of the R1 isolate, which provided the first completed genome sequence of B. microti. 21 The sequencing, assembly and annotation of the genome of this isolate was performed in collaboration between the Genoscope (Evry, France) and our teams at University of Montpellier in France and Yale University in the USA. The patient traveled to France where he was diagnosed to have babesiosis at the Centre Hospitalier Bretagne Atlantique in Vannes, Brittany. This report further highlights frequently encountered problems in the diagnosis of babesiosis, particularly in nonendemic regions of the world.
B. microti R1 genome analysis: biological and clinical implications
The assembly and annotation of the B. microti R1 genome made it possible to understand the metabolic functions of the parasite, identify new antigens for development of diagnostic assays, and identify targets for development of novel therapies. 24, 26 The parasite was first isolated from the blood of the patient and propagated in gerbils or hamsters. 21 The genome was then sequenced, annotated and made available on public genome databases. 21 Subsequent analyses included whole genome comparison between R1 and Gray strain isolates using optical mapping, determination of the structure and composition of the mitochondrial and apicoplast genomes. 22, 23 The size of the B. microti R1 nuclear genome is 6.5 MB, making it the smallest nuclear genome among apicomplexa. 21, 22 The genome consists of 4-chromosomes, has a G + C content of 36% and encodes 3567 protein-coding genes, most of which are expressed during parasite development in mammalian red blood cells. Phylogenetic analyses reveal that B. microti represents a new lineage within the phylum Apicomplexa, distinct from lineages encompassing Plasmodium sp. and true Babesia sp. (Figure 2A ). Despite its distinct evolution and until future renaming, the genus Babesia is still used for B. microti taxonomy and 
Areas of travel risk for babesiosis
Human babesiosis is endemic in the United States and China, 1,31 while sporadic cases occur in Europe (Figure 3) . B.
microti infection is endemic in the northeastern and northern Midwestern United States with the number of cases increasing significantly since the disease has become nationally notifiable in 2011. 2 In 2016, more than 1600 were reported to CDC.
Babesiosis is not a notifiable disease outside the USA and incidence of this disease is likely to be underestimated. Babesia divergens is the most common etiologic agent of babesiosis in Europe and splenectomized persons are at greater risk. 1 Most B.
microti cases reported in Europe are found in travelers coming from the USA. 7, 8, [11] [12] [13] 16 31, 38 There is concern that babesiosis may be misidentified as resistant malaria, given that both Plasmodium and Babesia parasites have a similar appearance on microscopic examination following Giemsa staining ( Figure 2B ) and that the Babesia parasites are less sensitive to chloroquine and mefloquine than Plasmodium parasites. 34 Physicians and other health care workers in areas where both babesiosis and malaria are endemic should order Babesia and malaria PCR, in addition to blood smears.
17,42

Babesiosis diagnosis
Babesiosis presents as a malaria-like illness without an easily recognizable sign. The diagnosis is therefore often delayed, especially We refer only to B. microti cases concerning immunocompetent patients. Babesia divergens, B. duncani, B. microti and B. venatorum are the major species infecting human across the world. Reference number is given in brackets in non-endemic regions. Because the malaria-like symptoms are non-specific (see below), health care workers in non-endemic areas often will not think of babesiosis and the diagnosis may first be made by laboratory personnel who recognize Babesia on a thin blood smear that was ordered as part of a complete blood count (CBC) or a peripheral smear requested for workup of malaria. Consequently, health care workers and laboratory personnel must include babesiosis in their differential diagnosis, especially because of the worldwide emergence of the disease and the increase in international travel. Babesiosis should be considered in any patient experiencing a malaria-like illness, including fever, fatigue, chills, sweats, headache and/or muscle aches. Other symptoms include anorexia, nausea, arthralgia and emotional lability. 1, 2 There are few findings on physical examination other than fever and occasional splenomegaly and/or hepatomegaly. A thorough travel history is important to obtain in such patients, including travel within any Babesia-endemic areas. It is also important to ask about blood transfusion within the previous 6 months because of the possibility of having received a transfusion of Babesia contaminated blood. Babesia microti is the most common pathogen transmitted by blood transfusion in the USA. [1] [2] [3] Due to the absence of routine screening of blood for Babesia infection and the transport of blood products from endemic to nonendemic areas, Babesia infection from blood transfusion can occur in both endemic and non-endemic areas. [4] [5] [6] Useful laboratory screening tests for patients include a CBC that usually shows hemolytic anemia and thrombocytopenia. 43 Liver enzymes are often elevated. Of note, thrombocytopenia and elevated transaminases also may be observed during A. phagocytophilum infection. Specific diagnosis is made by identification of Babesia on a Giemsa or Wright-stained thin blood smear, or PCR amplification of Babesia DNA with specific primers. There is a risk of mis-interpretation of intra-erythrocytic microorganisms on blood smear as B. microti or P. falciparum ( Figure 2B ). Distinguishing features of Babesia include tetrad merozoite forms ('Maltese Cross') that are pathognomonic for Babesia and the absence of pigment inclusions and visible gametocytes. Again, a travel history is often useful in distinguishing between babesiosis and malaria. PCR is more sensitive and specific than blood smear so that infections with as few as three parasites per 100µl of blood can yield a positive result. [44] [45] [46] [47] PCR usually is performed with two specific primers design in the 18S gene such as piroA/piroB, 25 as used for our patient or BAB1/BAB4. 44 Use of specific PCR primers or DNA sequencing of PCR products is necessary to identify various Babesia species such as B. microti, B. divergens, B. duncani and B. venatorum. Serology with IFA or ELISA is another useful laboratory test that may be positive at presentation because diagnosis is often delayed, giving time for production of antibody. Alternatively, the presence of IgG antibody may be due to past infection. In the case of the R1 patient, the serological analysis for B. microti was positive for IgM and IgG while that for malaria was negative for IgM but positive for IgG, most likely due to crossreactivity of IgG against P. falciparum antigens. Cross-reactivity between antigens of different hemoparasites has previously been described for Babesia bovis and P. falciparum.
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Babesiosis therapy: Current therapy for the treatment of B. microti-human babesiosis consists primarily of the combination of atovaquone and azithromycin. 49, 50 Clindamycin and quinine is used for severe disease. This combination is recommended for babesiosis resulting from B. divergens infections which are almost always severe. 50 The recommended duration of therapy is 7-10 days in most cases. Clinical improvement is usually observed within 48-72 h. In highly immunocompromised patients with severe disease who do not respond well to a standard duration of therapy, a more extended course of at least 6 weeks (including 2 weeks with repeatedly negative blood smears) is recommended. 1,2,51 Such patients include those with malignancy and rituximab treatment (especially B cell lymphoma and asplenia), HIV/AIDS, autoimmune disease treated with rituximab and organ transplantation treated with immunosuppressive agents. 51 The risk-benefit ratio of more prolonged therapy must be considered, especially with quinine that can lead to gastrointestinal distress, hearing impairment including tinnitis and/or cardiac impairment. 2, 49 Intravenous quinine or quinidine treatment may be given in the early phase of severe infection but should only be given in an ICU with cardiac monitoring. Our patient initially had insufficient improvement on quinine monotherapy so that addition of clindamycin to the quinine regimen was used to clear the infection. The current antibiotics used for treatment of babesiosis generally are effective but newer antimicrobial regimens are needed, especially for severe disease. Although quinine is often used for treatment of severe babesiosis, the side effects associated with this drug, the lack of evidence that B. microti degrades hemoglobin, and the inability of the compound to inhibit growth of the parasite in mice all suggest that its use for babesiosis treatment should be reevaluated. Atovaquone is a useful anti-Babesia drug with fewer side effects. The drug irreversibly binds to the mitochondrial cytochrome bc1 complex and blocks the electron flux in the mitochondrial inner membrane, which plays a central role in parasite physiology. However, resistance alleles have been found in the cytochrome b (cytb) gene on the mitochondrial genome. 48 The combination of atovaquone with endochin-like quinolone (ELQ) has shownpromise in preclinical studies 52 and awaits clinical evaluation. Azithromycin and clindamycin are suspected to target the ribosome of the apicoplast or the mitochondria, and are used in separate combination therapy regimens. Sensitivity of B. microti to artemisinin has been demonstrated in rodent models but efficacy in humans is still unknown.
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Partial or complete exchange blood transfusion is recommended in patients with high grade parasitemia (≥10%), significant hemolysis, or renal, hepatic or pulmonary compromise. Patients who are susceptible to severe babesiosis include those with asplenia, cancer, organ transplantation, HIV, hemoglobinopathies, those who acquire babesiosis through blood transfusion, are on immunosuppressive drugs, have chronic heart, lung or liver disease, or are neonates or elderly. Mortality rates of many such patients are about 20% even with antibiotic therapy.
1,51
Coinfection in tick-borne disease complicates both diagnosis and therapy Lyme disease coinfection may therefore enhance the emergence of babesiosis. Lyme disease patients who are coinfected with either B. microti or A. phagocytophilum experience a greater number of symptoms for longer duration than those with Lyme disease alone. 60 Coinfection should be considered in patients with more severe Lyme disease or patients who do not respond well to standard Lyme disease therapy. Finally, gene transfer between coinfecting microbes may occur. Genome sequencing of the B. microti R1 isolate provided evidence for lateral transfer of a Bartonella gene encoding a putative thiamin pyrophosphokinase into the B. microti genome. 21 The possible impacts of these genetic events on clinical severity or antibiotic resistance remains unknown. The diagnosis of Lyme disease and coinfection with babesiosis was considered in the R1 patient because of the detection of B. burgdorferi IgG antibody. The absence of an erythema migrans rash and IgM antibody indicated that the patient did not have acute Lyme disease but had experienced Lyme disease in the past. Simultaneous infection with Babesia and non tickborne pathogens may occur.
Conclusions
The B. microti R1 parasite isolated from the blood of the patient described in this report sat the stage for the genomic analysis of this parasite, which in turns has helped advance our understanding of the parasite's biology and pathogenesis and identify new targets for development of more sensitive diagnostic assays and more effective therapies. The diagnosis of babesiosis in non-endemic areas requires knowledge of the disease among health care workers and microbiology laboratory personnel. A travel history or history of blood transfusion within the 6 months preceding clinical evaluation is often important in making a correct diagnosis. Health care workers should consider coinfection with other Ixodes-borne pathogens in any patient with babesiosis. Severe disease may occur in immunocompromised hosts and those who acquire the infection through blood transfusion. Current treatment of babesiosis consists of atovaquone and azithromycin or clindamycin and quinine as an alternative treatment for severe disease. Current therapy for babesiosis is generally effective but new therapies, especially for severe disease are needed. 
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